Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Alexion Pharma (ALXN) a High Conviction Idea at Citi as 10-Q Overhang Removed
January 5, 2017 9:04 AM ESTCiti analyst Robyn Karnauskas called Alexion Pharma (NASDAQ: ALXN) a 2017 high conviction 'Buy' idea after the 10-Q overhang was lifted with no restatement.
She expects: 1) no restatement & 2) maintaining 2016 guidance will be considered positive by the street.
"We see 2017 guidance... More
